Corporate update from portfolio company Harpoon Therapeutics (1301829)
14 March 2022 - 10:32PM
UK Regulatory
Arix Bioscience PLC (ARIX) Corporate update from portfolio
company Harpoon Therapeutics 14-March-2022 / 11:32 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS
Group. The issuer is solely responsible for the content of this
announcement.
-----------------------------------------------------------------------------------------------------------------------
PRESS RELEASE
Arix Bioscience plc
Corporate update from portfolio company Harpoon Therapeutics
LONDON, 14 March 2022: Arix Bioscience plc ("Arix", LSE: ARIX),
a global venture capital company focused on investing in and
building breakthrough biotech companies, notes the recent
announcement from Harpoon Therapeutics, Inc. (Nasdaq: HARP) of its
financial results for the fourth quarter and full year of 2021, in
which the company provided a corporate update.
Following a thorough analysis of its HPN424 data, including
clinical results to date, the company decided to discontinue the
phase 1/2 dose escalation study for HPN424 in patients with
metastatic castration-resistant prostate cancer. The
discontinuation will allow Harpoon to concentrate on HNP328, in
development for tumours associated with delta like ligand 3 (DLL3)
expression, and HPN 217 for BCMA.
Earlier in March, Harpoon announced the granting of Orphan Drug
Designation for HPN328 in small cell lung cancer and Fast Track
designation for HPN2178 in relapsed, refractory multiple myeloma.
Studies to determine the recommended phase 2 dose for both
candidates are expected to complete this year.
The full text of the Harpoon announcement can be accessed
here.
[ENDS]
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
ir@arixbioscience.com
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil
+44 (0)20 7250 1446
arix@powerscourt-group.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused
on investing in and building breakthrough biotech companies around
cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the
capital, expertise and global networks to help accelerate their
ideas into important new treatments for patients. As a listed
company, we are able to bring this exciting growth phase of our
industry to a broader range of investors.
www.arixbioscience.com
-----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: PFU
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 148920
EQS News ID: 1301829
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1301829&application_name=news
(END) Dow Jones Newswires
March 14, 2022 07:32 ET (11:32 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2023 to Apr 2024